Outpatient diagnostic imaging sits in a tricky spot. Scan volumes tend to rise with an ageing population and more preventive care, but reimbursement pressure and price competition keep margins thin, which has historically limited how much value investors are willing to assign to these businesses. Artificial intelligence is starting to change that equation. Clinical grade tools can speed up reading, triage cases, automate parts of the report and optimise scheduling, which lifts machine utilisation and radiologist productivity rather than just adding another cost line.

One of the largest outpatient imaging chains in the US has leaned into this shift with a roll up strategy and an AI shopping spree, building a network of several hundred sites and acquiring multiple software and workflow vendors to embed AI into everyday operations. The share price, however, has corrected by roughly 50 percent from last year’s high, as higher leverage and deal spending collided with investor worries about…